Adapting asthma clinical trials in response to the COVID-19 pandemic - the BenRex study design
S. Smith (Glasgow, United Kingdom), L. Gillespie (Glasgow, United Kingdom), L. Heaney (Belfast, United Kingdom), C. Brightling (Leicester, United Kingdom), A. Mcconnachie (Glasgow, United Kingdom), S. Siddiqui (Lecester, United Kingdom), V. Mistry (Lecester, United Kingdom), V. Brown (Belfast, United Kingdom), D. Jackson (London, United Kingdom), N. Lee (Glasgow, United Kingdom), S. Fowler (Manchester, United Kingdom), A. Mansur (Birmingham, United Kingdom), H. Burhan (Liverpool, United Kingdom), D. Saralaya (Bradford, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom), S. Nasser (Cambridge, United Kingdom), P. Pfeffer (London, United Kingdom), T. Brown (Portsmouth, United Kingdom), J. Lordan (Newcastle, United Kingdom), I. Pavord (Oxford, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom)
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Smith (Glasgow, United Kingdom), L. Gillespie (Glasgow, United Kingdom), L. Heaney (Belfast, United Kingdom), C. Brightling (Leicester, United Kingdom), A. Mcconnachie (Glasgow, United Kingdom), S. Siddiqui (Lecester, United Kingdom), V. Mistry (Lecester, United Kingdom), V. Brown (Belfast, United Kingdom), D. Jackson (London, United Kingdom), N. Lee (Glasgow, United Kingdom), S. Fowler (Manchester, United Kingdom), A. Mansur (Birmingham, United Kingdom), H. Burhan (Liverpool, United Kingdom), D. Saralaya (Bradford, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom), S. Nasser (Cambridge, United Kingdom), P. Pfeffer (London, United Kingdom), T. Brown (Portsmouth, United Kingdom), J. Lordan (Newcastle, United Kingdom), I. Pavord (Oxford, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom). Adapting asthma clinical trials in response to the COVID-19 pandemic - the BenRex study design. 1108
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Clinical trials during the COVID-19 pandemic: research design and lessons Source: Eur Respir Monogr 2021; 94: 214-231 Year: 2021
A non-interventional observational trial to study the COPD treatment choices in routine clinical practice in Bulgaria Source: International Congress 2016 – COPD diagnosis and management Year: 2016
ISARIC Covid-19 pandemic research response, tools and outcomes from clinical characterisation studies Source: Virtual Congress 2020 – New developments in pandemic medicine Year: 2020
The Spanish national clinical audit on COPD exacerbations (eCOPD). Pilot study: selection of study subjects Source: Annual Congress 2008 - COPD in the elderly - quality of life and scores in COPD Year: 2008
A trial like ALIC4 E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness? Source: ERJ Open Res, 4 (2) 00046-2018; 10.1183/23120541.00046-2018 Year: 2018
A smart mHealth tool versus a paper action plan to support self-management of COPD exacerbations: a randomised controlled trial Source: International Congress 2019 – M-health/e-health I Year: 2019
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response Source: Eur Respir Rev 2014; 23: 367-378 Year: 2014
Negative clinical trials in sarcoidosis: failed therapies or flawed study design? Source: Eur Respir J 2014; 44: 1123-1126 Year: 2014
The Spanish national clinical audit on COPD exacerbations. Results of a pilot study: main outcomes Source: Annual Congress 2008 - Prognosis in COPD Year: 2008
A personalised management programme of difficult asthma: a prospective study Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007
COPD integrated disease management, from controlled trial to real-world primary care; a cohort study. Source: Virtual Congress 2020 – Organising respiratory disease management in primary care Year: 2020
Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability Source: Eur Respir J, 51 (2) 1701531; 10.1183/13993003.01531-2017 Year: 2018
No gender-related bias in COPD diagnosis and treatment in Sweden: a randomised, controlled, case-based trial Source: ERJ Open Res, 6 (4) 00342-2020; 10.1183/23120541.00342-2020 Year: 2020
Clinical effectiveness of self-management of asthma in general practice: a randomized controlled trial Source: Eur Respir J 2001; 18: Suppl. 33, 518s Year: 2001
The long-term clinical and economic impact of COPD exacerbations: an observational study (SHERLOCK) Source: Virtual Congress 2020 – Prediction and management of outcomes in obstructive diseases Year: 2020
The Spanish national clinical audit on COPD exacerbations. results of a pilot study: spirometry outcomes Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008
The coping with asthma study: a randomised controlled trial and economic evaluation of a home-based nurse intervention for adults at risk of adverse asthma outcomes Source: Eur Respir J 2003; 22: Suppl. 45, 536s Year: 2003
Quality and methodology of clinical practice guidelines on antiviral pharmacotherapy for COVID-19 during the early phase of the pandemic Source: Virtual Congress 2021 – COVID - 19: lessons learned Year: 2021